Skip to content
10-Q

Quarterly Report

CRESCENT BIOPHARMA, INC. CBIO

0001628280-25-049868

← back to feed
Filed
Nov 6, 2025 12:00 AM ET
Period of report
Restated figures. One or more values in this filing restate previously reported amounts.

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q3 2025 · Nov 3, 2025 13.89M sh
Capex Q3 2025 · Sep 30, 2025 $726K
Capex Q3 2025 · Sep 30, 2024 $0
Operating Cash Flow Q3 2025 · Sep 30, 2025 −$44.79M
Operating Cash Flow Q3 2025 · Sep 30, 2024 $0
Cash And Equivalents Q3 2025 · Sep 30, 2025 $133.27M
Cash And Equivalents Q3 2025 · Dec 31, 2024 $34.77M
Stockholders Equity Q3 2025 · Sep 30, 2025 $116.64M
Stockholders Equity Q3 2025 · Jun 30, 2025 $139.25M
Stockholders Equity Q3 2025 · Mar 31, 2025 −$30.16M
Stockholders Equity Q3 2025 · Dec 31, 2024 −$15.48M
Stockholders Equity restated Q3 2025 · Sep 30, 2024 −$1.3M
Stockholders Equity Q3 2025 · Sep 19, 2024 $0
Current Liabilities Q3 2025 · Sep 30, 2025 $20.3M
Current Liabilities Q3 2025 · Dec 31, 2024 $9.61M
Total Liabilities Q3 2025 · Sep 30, 2025 $21.63M
Total Liabilities Q3 2025 · Dec 31, 2024 $47.1M
Current Assets Q3 2025 · Sep 30, 2025 $134.56M
Current Assets Q3 2025 · Dec 31, 2024 $34.8M
Total Assets Q3 2025 · Sep 30, 2025 $138.27M
Total Assets Q3 2025 · Dec 31, 2024 $35.62M
Rd Expense Q3 2025 · Sep 30, 2025 $20.35M
Rd Expense Q3 2025 · Sep 30, 2025 $43.06M
Rd Expense Q3 2025 · Sep 30, 2024 $2.47M
Net Income Q3 2025 · Sep 30, 2025 −$24.61M
Net Income Q3 2025 · Sep 30, 2025 −$61.55M
Net Income Q3 2025 · Jun 30, 2025 −$21.79M
Net Income Q3 2025 · Mar 31, 2025 −$15.15M
Net Income Q3 2025 · Sep 30, 2024 −$2.63M
Operating Income Q3 2025 · Sep 30, 2025 −$25.89M
Operating Income Q3 2025 · Sep 30, 2025 −$61.14M
Operating Income Q3 2025 · Sep 30, 2024 −$2.63M